Clinical response to sodium glucose co‐transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma

INTRODUCTION: Sodium glucose co‐transporter 2 inhibitors constitute a new class of antidiabetic medication. Sodium glucose co‐transporter 2 inhibitors have been shown to exert anticancer effects. However, the clinical value of these drugs as anticancer agents is yet to be evaluated. CASE PRESENTATIO...

Descripción completa

Detalles Bibliográficos
Autores principales: Izumi, Keita, Iimura, Yasumasa, Hiruma, Kiyoshi, Touma, Tsuguhiro, Tsukamoto, Tetsuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292183/
https://www.ncbi.nlm.nih.gov/pubmed/32743434
http://dx.doi.org/10.1002/iju5.12099
_version_ 1783546056926035968
author Izumi, Keita
Iimura, Yasumasa
Hiruma, Kiyoshi
Touma, Tsuguhiro
Tsukamoto, Tetsuro
author_facet Izumi, Keita
Iimura, Yasumasa
Hiruma, Kiyoshi
Touma, Tsuguhiro
Tsukamoto, Tetsuro
author_sort Izumi, Keita
collection PubMed
description INTRODUCTION: Sodium glucose co‐transporter 2 inhibitors constitute a new class of antidiabetic medication. Sodium glucose co‐transporter 2 inhibitors have been shown to exert anticancer effects. However, the clinical value of these drugs as anticancer agents is yet to be evaluated. CASE PRESENTATION: A 72‐year‐old man presented to our hospital with frequent cough and dyspnea. Contrast‐enhanced computed tomography revealed renal cell carcinoma cT3bN0M1. Ipragliflozin, a sodium glucose co‐transporter 2 inhibitor, treatment was initiated to control blood glucose levels. Two years after diagnosis, computed tomography revealed remarkable tumor regression without any systemic therapy other than ipragliflozin. CONCLUSION: Sodium glucose co‐transporter 2 inhibitors are potentially applicable as anticancer agents among patients with metastatic renal cell carcinoma.
format Online
Article
Text
id pubmed-7292183
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-72921832020-07-30 Clinical response to sodium glucose co‐transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma Izumi, Keita Iimura, Yasumasa Hiruma, Kiyoshi Touma, Tsuguhiro Tsukamoto, Tetsuro IJU Case Rep Case Reports INTRODUCTION: Sodium glucose co‐transporter 2 inhibitors constitute a new class of antidiabetic medication. Sodium glucose co‐transporter 2 inhibitors have been shown to exert anticancer effects. However, the clinical value of these drugs as anticancer agents is yet to be evaluated. CASE PRESENTATION: A 72‐year‐old man presented to our hospital with frequent cough and dyspnea. Contrast‐enhanced computed tomography revealed renal cell carcinoma cT3bN0M1. Ipragliflozin, a sodium glucose co‐transporter 2 inhibitor, treatment was initiated to control blood glucose levels. Two years after diagnosis, computed tomography revealed remarkable tumor regression without any systemic therapy other than ipragliflozin. CONCLUSION: Sodium glucose co‐transporter 2 inhibitors are potentially applicable as anticancer agents among patients with metastatic renal cell carcinoma. John Wiley and Sons Inc. 2019-06-26 /pmc/articles/PMC7292183/ /pubmed/32743434 http://dx.doi.org/10.1002/iju5.12099 Text en © 2019 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Izumi, Keita
Iimura, Yasumasa
Hiruma, Kiyoshi
Touma, Tsuguhiro
Tsukamoto, Tetsuro
Clinical response to sodium glucose co‐transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma
title Clinical response to sodium glucose co‐transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma
title_full Clinical response to sodium glucose co‐transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma
title_fullStr Clinical response to sodium glucose co‐transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma
title_full_unstemmed Clinical response to sodium glucose co‐transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma
title_short Clinical response to sodium glucose co‐transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma
title_sort clinical response to sodium glucose co‐transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292183/
https://www.ncbi.nlm.nih.gov/pubmed/32743434
http://dx.doi.org/10.1002/iju5.12099
work_keys_str_mv AT izumikeita clinicalresponsetosodiumglucosecotransporter2inhibitoripragliflozininapatientwithmetastaticrenalcellcarcinoma
AT iimurayasumasa clinicalresponsetosodiumglucosecotransporter2inhibitoripragliflozininapatientwithmetastaticrenalcellcarcinoma
AT hirumakiyoshi clinicalresponsetosodiumglucosecotransporter2inhibitoripragliflozininapatientwithmetastaticrenalcellcarcinoma
AT toumatsuguhiro clinicalresponsetosodiumglucosecotransporter2inhibitoripragliflozininapatientwithmetastaticrenalcellcarcinoma
AT tsukamototetsuro clinicalresponsetosodiumglucosecotransporter2inhibitoripragliflozininapatientwithmetastaticrenalcellcarcinoma

Ejemplares similares